Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma
Launched by HADASSAH MEDICAL ORGANIZATION · Sep 21, 2011
Trial Information
Current as of August 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how certain substances in the blood, called serum biomarkers, can help diagnose metastatic uveal melanoma, which is a type of eye cancer that can spread to other parts of the body. The researchers believe that changes in these biomarkers might occur when the cancer starts to spread. If they can detect these changes early, it could allow for treatment before the cancer is visible on scans, potentially improving survival rates for patients.
To participate in this study, you need to have a diagnosis of uveal melanoma. The trial is open to everyone, regardless of age or gender, and is currently recruiting participants. If you join the trial, you will be tested for these biomarkers, and the hope is that it will lead to earlier and more effective treatment options if the cancer has spread. It's important to note that participation is completely voluntary, and you can choose not to be a part of the study if you prefer.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • diagnosis of uveal melanoma
- Exclusion Criteria:
- • refusal to participate in the study
About Hadassah Medical Organization
Hadassah Medical Organization (HMO) is a leading healthcare institution based in Jerusalem, Israel, renowned for its commitment to advancing medical research and improving patient care. As a prominent clinical trial sponsor, HMO leverages its state-of-the-art facilities and multidisciplinary expertise to conduct innovative research across various therapeutic areas. The organization is dedicated to fostering collaboration between clinical researchers, healthcare professionals, and academic institutions, ensuring the highest standards of ethical practice and scientific rigor. HMO's mission is to translate groundbreaking research into effective treatments, ultimately enhancing health outcomes for diverse populations both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jerusalem, , Israel
Patients applied
Trial Officials
Shahar Frenkel, MD, PhD
Principal Investigator
Hadassah Medical Organization
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials